Carcinocythemia detection in peripheral blood smears: a literature review.

IF 1.1 Q4 MEDICAL LABORATORY TECHNOLOGY
Advances in laboratory medicine Pub Date : 2026-03-16 eCollection Date: 2026-06-01 DOI:10.1515/almed-2025-0169
Javier Laguna, Anna Merino
{"title":"Carcinocythemia detection in peripheral blood smears: a literature review.","authors":"Javier Laguna, Anna Merino","doi":"10.1515/almed-2025-0169","DOIUrl":null,"url":null,"abstract":"<p><p>Carcinocythemia, or carcinoma cell leukemia, is a rare but striking manifestation of advanced malignancy in which circulating tumor cells (CTCs) are visible in peripheral blood (PB) smears using conventional staining. It is typically associated with advanced stage disease and poor prognosis. This review updates current knowledge on the pathophysiology, cytological features, detection methods, and clinical relevance of carcinocythemia. It explores mechanisms such as bone marrow infiltration, splenic dysfunction, and immune evasion that may facilitate tumor cell release into circulation. Morphologically, CTCs are large atypical cells often mistaken for hematologic blasts, with features that vary by tumor type. Immunocytochemistry using cytokeratins and epithelial markers (e.g. AE1/AE3, EpCAM) is crucial for confirmation. While most cases involve breast or lung cancer, other malignancies, ranging from melanoma to rhabdomyosarcoma, have also been implicated. Carcinocythemia often mimics acute leukemia and coexists with disseminated intravascular coagulation or thrombosis. To date, 95 cases have been reported, but its true prevalence may be underestimated. Recognition of this phenomenon in PB smear reviews is critical for accurate diagnosis and prognostication, especially in acutely ill or cytopenic patients. Further research is needed to elucidate its biology and clinical implications.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"7 2","pages":"90-104"},"PeriodicalIF":1.1000,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169457/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/almed-2025-0169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Carcinocythemia, or carcinoma cell leukemia, is a rare but striking manifestation of advanced malignancy in which circulating tumor cells (CTCs) are visible in peripheral blood (PB) smears using conventional staining. It is typically associated with advanced stage disease and poor prognosis. This review updates current knowledge on the pathophysiology, cytological features, detection methods, and clinical relevance of carcinocythemia. It explores mechanisms such as bone marrow infiltration, splenic dysfunction, and immune evasion that may facilitate tumor cell release into circulation. Morphologically, CTCs are large atypical cells often mistaken for hematologic blasts, with features that vary by tumor type. Immunocytochemistry using cytokeratins and epithelial markers (e.g. AE1/AE3, EpCAM) is crucial for confirmation. While most cases involve breast or lung cancer, other malignancies, ranging from melanoma to rhabdomyosarcoma, have also been implicated. Carcinocythemia often mimics acute leukemia and coexists with disseminated intravascular coagulation or thrombosis. To date, 95 cases have been reported, but its true prevalence may be underestimated. Recognition of this phenomenon in PB smear reviews is critical for accurate diagnosis and prognostication, especially in acutely ill or cytopenic patients. Further research is needed to elucidate its biology and clinical implications.

外周血涂片检测癌性红细胞增多症的文献综述。
癌性红细胞增多症或癌细胞白血病是一种罕见但显著的晚期恶性肿瘤表现,在常规染色的外周血(PB)涂片中可见循环肿瘤细胞(ctc)。它通常与疾病晚期和预后不良有关。这篇综述更新了目前关于癌性红细胞增多症的病理生理学、细胞学特征、检测方法和临床相关性的知识。它探讨了骨髓浸润、脾功能障碍和免疫逃避等可能促进肿瘤细胞释放进入循环的机制。形态学上,ctc是大的非典型细胞,常被误认为是造血母细胞,其特征因肿瘤类型而异。使用细胞角蛋白和上皮标记物(如AE1/AE3, EpCAM)的免疫细胞化学对确认至关重要。虽然大多数病例涉及乳腺癌或肺癌,但其他恶性肿瘤,从黑色素瘤到横纹肌肉瘤,也有牵连。癌性红细胞血症常与急性白血病相似,并伴有弥散性血管内凝血或血栓形成。迄今为止,已报告了95例,但其真实患病率可能被低估。在PB涂片检查中认识到这一现象对于准确诊断和预测至关重要,特别是在急性疾病或细胞减少的患者中。需要进一步的研究来阐明其生物学和临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书